Lords Committee Putting Life Sciences Under The Microscope
Date posted:
News
Later this month the House of Lords Science and Technology Committee will be examining evidence as part of an inquiry to determine whether the government has put the right structures in place to support the UK’s life sciences industry, as well as looking at the contents of the industrial strategy and how the NHS could use procurement to further innovation.
Two oral evidence sessions have been scheduled for 17 October and 24 October, when the committee will hear submissions from people across the life sciences sector.
During the first session, Sir Andrew Dillon, chief executive for the National Institute for Health and Care Excellence, and Mr Menelas Pangalos, executive vice president for the innovative medicine and early development (IMED) biotech unit at AstraZeneca, will be among those giving their views.
In the second session there will be submissions from the heads of three NHS foundation trusts, as well as the head of policy and public affairs at the Association of Medical Research Charities Ms Nisha Tailor.
Pharmaphorum suggested that one of the areas the committee may examine is whether the life sciences minister role should be reinstated. The position was originally created in 2014, but the role was then scrapped following the Brexit referendum.
The responsibilities held by this position were then divided between ministers in the Department of Health and the Department for Business, Energy and Industrial Strategy.
If you need assistance with your life sciences sales pipeline, contact us today to find out how you could tap into our expertise in this area.